Home - Products - Inhibitors & Agonists - Epigenetics Library - Details

JAK 3i CAS No.: 1918238-72-8

Chemical Structure : JAK 3i
CAS No.: 1918238-72-8

Send Inquiry

Description

Chemical Structure : JAK 3i

CAS No.: 1918238-72-8

JAK 3i

Catalog No.: URK-V2504 Only Used For Lab.

JAK 3i is a promising drug candidate that has been developed to inhibit the activity of Janus Kinase 3 (JAK3), an enzyme that is involved in the signaling pathways of cytokines and growth factors. JAK3 plays an important role in the development of inflammatory and autoimmune diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis, and ulcerative colitis. By selectively targeting JAK3, JAK 3i could potentially provide a new treatment option for these diseases.

Biological Activity

The principle of JAK 3i's inhibitory action is through binding to the ATP-binding site of JAK3 and preventing the phosphorylation and activation of downstream signaling pathways. By inhibiting JAK3 activity, JAK 3i can reduce the production of pro-inflammatory cytokines and chemokines, and thus reduce inflammation and tissue damage.
In recent years, JAK inhibitors have emerged as a promising class of drugs for the treatment of inflammatory and autoimmune diseases. FDA has approved several JAK inhibitors, including tofacitinib and baricitinib, for the treatment of rheumatoid arthritis. However, these drugs have limitations in terms of efficacy and safety. JAK 3i, as a selective JAK3 inhibitor, may have a better safety profile and fewer adverse effects.
Several studies have been conducted to investigate the efficacy and safety of JAK 3i in animal models of inflammatory and autoimmune diseases. These studies have shown promising results, demonstrating that JAK 3i can effectively reduce inflammation and ameliorate disease symptoms.
In conclusion, JAK 3i is a promising drug candidate for the treatment of inflammatory and autoimmune diseases, with a unique mechanism of action and potential advantages over existing JAK inhibitors. Further clinical trials are needed to evaluate its efficacy and safety in human patients.

Physicochemical Properties

M.Wt	354.34
Formula	C₁₈H₁₅FN₄O₃
CAS No.	1918238-72-8
Appearance	Solid
Storage	Solide Powder -20 °C 3years; 4°C 2years	In Solvent -80°C 6 Months -20°C 1 Months
Solubility
Chemical Name

References

1. Kitzmüller C, Sexl V, Scherzer J, et al. The impact of Janus kinase 3 inhibition on regulatory T cells: A new therapeutic approach in autoimmune disease? Pharmacol Ther. 2020;213:107562.

2. Rubbert-Roth A, Guo Q, Biswas R, et al. Trial of Upadacitinib and Abatacept in Rheumatoid Arthritis (SELECT-EARLY): A Multi-Center, Randomized, Double-Blind, Parallel-Group, Active Comparator-Controlled Phase 3 Trial. Lancet. 2021;397(10277):2516-2528.

3. Yiu ZZ, Krueger JG, Lebwohl MG. What's New in Psoriasis Research and Treatment? Dermatol Clin. 2021;39(2):203-211.